Bausch & Lomb Stellaris PC
This article was originally published in The Gray Sheet
Executive Summary
Firm announces Aug. 19 510(k) clearance of its Stellaris PC (Procedural Choice) vision enhancement system for cataract, retina and combined cataract/retina surgery. The product is a combined vitrectomy and phacoemulsification system. Stellaris was originally cleared in 2007 for cataract surgery only; the new multi-procedure system gained CE mark approval in May (1"The Gray Sheet" Aug. 23, 2010)
You may also be interested in...
New Products In Brief
Bausch & Lomb's Stellaris PC: Company debuts its Stellaris PC (Procedural Choice) vision enhancement system overseas following CE mark approval last May. The combined vitrectomy and phacoemulsification system, for which a May 510(k) submission remains pending at FDA, enhances surgeons' ability to see ocular tissue under various surgical conditions, B&L claims. Stellaris PC is indicated for emulsification and removal of cataracts, and anterior and posterior segment vitrectomy
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.